Tech Company Financing Transactions
Switch Therapeutics Funding Round
Insight Venture Partners, UCB Ventures and Bold Capital Partners invested in a $52 million Series A funding round for Switch Therapeutics. The round was announced on 3/14/2023.
Transaction Overview
Company Name
Announced On
3/14/2023
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to select and advance a development candidate for its lead program for the treatment of a central nervous system disease, explore opportunities to expand its CASi platform into new areas through potential pharmaceutical collaborations, and recruit top R&D and corporate talent to help accelerate its growth
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
241 East Harris Avenue South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Switch Therapeutics was founded in 2020 to develop therapeutic applications from RNAi research conducted at Caltech, Harvard Medical School and City of Hope. In early 2022, Switch Therapeutics moved out of MBC Biolabs, an incubator facility, and into its own facility in South San Francisco and upon raising $52M of financing, publicly announced its launch.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dee Datta
Chief Technical Officer
Si-ping Han
Vice President
Don Button
Vice President
Robert Duff
Browse more venture capital transactions:
Prev: 3/14/2023: Monarx venture capital transaction
Next: 3/14/2023: Smooth Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs